JP2018528773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528773A5 JP2018528773A5 JP2018512167A JP2018512167A JP2018528773A5 JP 2018528773 A5 JP2018528773 A5 JP 2018528773A5 JP 2018512167 A JP2018512167 A JP 2018512167A JP 2018512167 A JP2018512167 A JP 2018512167A JP 2018528773 A5 JP2018528773 A5 JP 2018528773A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 75
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 102000008166 Member 25 Tumor Necrosis Factor Receptors Human genes 0.000 claims 3
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022005039A JP7341259B2 (ja) | 2015-09-18 | 2022-01-17 | Ｔｌ１ａに特異的に結合する抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220442P | 2015-09-18 | 2015-09-18 | |
| US62/220,442 | 2015-09-18 | ||
| PCT/US2016/052040 WO2017049024A1 (en) | 2015-09-18 | 2016-09-16 | Antibodies that specifically bind to tl1a |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022005039A Division JP7341259B2 (ja) | 2015-09-18 | 2022-01-17 | Ｔｌ１ａに特異的に結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528773A JP2018528773A (ja) | 2018-10-04 |
| JP2018528773A5 true JP2018528773A5 (enExample) | 2019-10-24 |
| JP7013366B2 JP7013366B2 (ja) | 2022-02-15 |
Family
ID=57043002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512167A Active JP7013366B2 (ja) | 2015-09-18 | 2016-09-16 | Ｔｌ１ａに特異的に結合する抗体 |
| JP2022005039A Active JP7341259B2 (ja) | 2015-09-18 | 2022-01-17 | Ｔｌ１ａに特異的に結合する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022005039A Active JP7341259B2 (ja) | 2015-09-18 | 2022-01-17 | Ｔｌ１ａに特異的に結合する抗体 |
Country Status (33)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| MX2014003689A (es) | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| WO2017096358A1 (en) * | 2015-12-04 | 2017-06-08 | University Of Iowa Research Foundation | Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| CN118240830A (zh) | 2016-10-26 | 2024-06-25 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
| ES3066090T3 (en) * | 2017-04-28 | 2026-05-11 | Ajinomoto Co Inc | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| CN114901311A (zh) | 2019-10-24 | 2022-08-12 | 普罗米修斯生物科学公司 | Tnf样配体1a（tl1a）的人源化抗体及其用途 |
| KR20230051581A (ko) * | 2020-08-19 | 2023-04-18 | 얀센 바이오테크 인코포레이티드 | 조작된 리간드를 사용하는 물질 및 방법 |
| WO2022178158A1 (en) * | 2021-02-18 | 2022-08-25 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the lung |
| IL318297A (en) | 2022-07-27 | 2025-03-01 | Cephalon Llc | Anti-TL1A antibody formulations |
| CA3262839A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE |
| IL324671A (en) | 2023-05-17 | 2026-01-01 | Genentech Inc | Anti-tl1a antibody therapeutic methods |
| WO2024263868A2 (en) * | 2023-06-21 | 2024-12-26 | Paragon Therapeutics, Inc. | Tl1a antibody compositions and methods of use |
| WO2024263900A2 (en) * | 2023-06-22 | 2024-12-26 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2024263945A2 (en) * | 2023-06-22 | 2024-12-26 | Paragon Therapeutics, Inc. | Il-17 antibody compositions and methods of use |
| IL325993A (en) | 2023-08-11 | 2026-03-01 | Paragon Therapeutics Inc | TL1A binding proteins and methods of use |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| CN120058933B (zh) * | 2023-11-30 | 2026-02-10 | 北京智仁美博生物科技有限公司 | 抗肿瘤坏死因子样配体1a的抗体及其用途 |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| CN120424214A (zh) * | 2024-02-05 | 2025-08-05 | 三生国健药业（上海）股份有限公司 | 一种抗tl1a抗体及其制备方法和用途 |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| CN120590530A (zh) * | 2024-03-05 | 2025-09-05 | 帆礼生物技术(武汉)有限公司 | 靶向tl1a的抗体及其应用 |
| US20250376530A1 (en) | 2024-05-17 | 2025-12-11 | Genentech, Inc. | Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody |
| WO2026072993A1 (en) | 2024-09-27 | 2026-04-02 | Genentech, Inc. | Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody |
| WO2026072983A1 (en) | 2024-09-27 | 2026-04-02 | Genentech, Inc. | Methods for treatment of atopic dermatitis with an anti-tl1a antibody |
| CN119552252B (zh) * | 2025-01-16 | 2025-11-25 | 华润生物医药有限公司 | 抗tl1a抗体及其制备方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| BRPI0509201A (pt) | 2004-03-23 | 2007-08-28 | Biogen Idec Inc | agentes de acoplamento de receptor e usos terapêuticos destes |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| BRPI0617057A2 (pt) | 2005-08-30 | 2011-07-12 | Univ Miami | anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão |
| WO2007076465A2 (en) | 2005-12-23 | 2007-07-05 | Diadexus, Inc. | Cln248 antibody compositions and methods of use |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2009052512A2 (en) | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| MX2010005282A (es) | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| WO2010118210A1 (en) | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| EP2519260A2 (en) | 2009-12-31 | 2012-11-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| AU2012259312A1 (en) | 2011-05-20 | 2013-12-12 | Government Of The United States, As Represented By The Secretary Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| WO2012174338A2 (en) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Method of selecting therapeutic indications |
| MX2014003689A (es) * | 2011-09-30 | 2014-12-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos contra tl1a y sus usos. |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| EA201591153A1 (ru) | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| HK1220919A1 (zh) * | 2013-04-05 | 2017-05-19 | F. Hoffmann-La Roche Ag | 抗il-4抗体和双特异性抗体及其用途 |
| CN105358713B (zh) | 2013-05-17 | 2020-02-28 | 雪松-西奈医学中心 | 与克罗恩病相关的tnfsf15和dcr3的变体 |
| EP2996717A4 (en) | 2013-05-17 | 2016-11-23 | Cedars Sinai Medical Center | DIFFERENT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A-MODULATED INFLAMMATION AND FIBROSIS |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| WO2015035261A1 (en) | 2013-09-06 | 2015-03-12 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-tl1a therapy |
| EP3068801A1 (en) * | 2013-11-13 | 2016-09-21 | Pfizer Inc. | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
| US10519485B2 (en) | 2015-04-15 | 2019-12-31 | Biosearch Technologies, Inc. | Dual quencher probes |
| US20180156781A1 (en) | 2015-05-15 | 2018-06-07 | Cedars-Sinai Medical Center | Models, methods and compositions for treating inflammatory bowel disease |
| CA2994719A1 (en) | 2015-08-21 | 2017-03-02 | The Children's Hospital Of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US20180319889A1 (en) | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| US10968279B2 (en) | 2016-05-09 | 2021-04-06 | Bristol-Myers Squibb Company | TL1A antibodies and uses thereof |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| MX389320B (es) | 2016-06-09 | 2025-03-20 | Pelican Therapeutics Inc | Anticuerpos anti-tnfrsf25 |
| CN118240830A (zh) | 2016-10-26 | 2024-06-25 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
| US10626180B2 (en) | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| MA52251A (fr) | 2018-04-30 | 2021-02-17 | Cedars Sinai Medical Center | Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires |
| CA3121167A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| WO2021081365A1 (en) | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2021108694A1 (en) | 2019-11-27 | 2021-06-03 | Cedars-Sinai Medical Center | Predicting extraintestinal manifestations of inflammatory bowel disease |
| WO2021247548A1 (en) | 2020-06-03 | 2021-12-09 | Cedars-Sinai Medical Center | Treatments for a sub-population of inflammatory bowel disease patients |
| WO2021247770A1 (en) | 2020-06-03 | 2021-12-09 | Cedars-Sinai Medical Center | Methods and systems for measuring post-operative disease recurrence |
| CN116322762A (zh) | 2020-06-26 | 2023-06-23 | 辉瑞公司 | 用tl1a抗体治疗炎症性肠病的方法 |
| JP2023551602A (ja) | 2020-11-13 | 2023-12-08 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット |
| EP4256086A4 (en) | 2020-12-01 | 2025-01-15 | Cedars-Sinai Medical Center | METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES |
| WO2022140283A1 (en) | 2020-12-21 | 2022-06-30 | Cedars-Sinai Medical Center | Tl1a therapy compositions and methods of treatment therewith |
| IL305312A (en) | 2021-02-18 | 2023-10-01 | Prometheus Biosciences Inc | Compositions comprising human antibodies to TNF-like ligand 1A (TL1A) and uses thereof |
| WO2022178158A1 (en) | 2021-02-18 | 2022-08-25 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the lung |
| WO2022232253A1 (en) | 2021-04-28 | 2022-11-03 | Cedars-Sinai Medical Center | Patient selection methods and kits for therapies targeting tl1a |
| WO2023102071A1 (en) | 2021-12-01 | 2023-06-08 | Cedars-Sinai Medical Center | Microbial metabolites on intestinal inflammation |
| WO2023102051A1 (en) | 2021-12-01 | 2023-06-08 | Cedars-Sinai Medical Center | Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease |
| AR128226A1 (es) | 2022-01-07 | 2024-04-10 | Prometheus Biosciences Inc | Métodos para tratar enfermedades inflamatorias con una combinación de inhibidores de tl1a e inhibidores de il23 |
| US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
-
2016
- 2016-09-14 TW TW105130075A patent/TWI703158B/zh active
- 2016-09-16 ES ES16774750T patent/ES2810751T3/es active Active
- 2016-09-16 PE PE2018000398A patent/PE20181080A1/es unknown
- 2016-09-16 MD MDE20180714T patent/MD3350223T2/ro unknown
- 2016-09-16 LT LTEP16774750.0T patent/LT3350223T/lt unknown
- 2016-09-16 WO PCT/US2016/052040 patent/WO2017049024A1/en not_active Ceased
- 2016-09-16 SM SM20200500T patent/SMT202000500T1/it unknown
- 2016-09-16 KR KR1020187007337A patent/KR101998535B1/ko active Active
- 2016-09-16 MA MA42825A patent/MA42825B1/fr unknown
- 2016-09-16 PL PL16774750T patent/PL3350223T3/pl unknown
- 2016-09-16 JP JP2018512167A patent/JP7013366B2/ja active Active
- 2016-09-16 AR ARP160102834A patent/AR106055A1/es unknown
- 2016-09-16 UA UAA201804192A patent/UA125284C2/uk unknown
- 2016-09-16 PH PH1/2018/500580A patent/PH12018500580B1/en unknown
- 2016-09-16 EP EP16774750.0A patent/EP3350223B1/en active Active
- 2016-09-16 EP EP20151834.7A patent/EP3693393A1/en active Pending
- 2016-09-16 HR HRP20201323TT patent/HRP20201323T1/hr unknown
- 2016-09-16 PT PT167747500T patent/PT3350223T/pt unknown
- 2016-09-16 DK DK16774750.0T patent/DK3350223T3/da active
- 2016-09-16 BR BR122021002400A patent/BR122021002400A8/pt not_active Application Discontinuation
- 2016-09-16 RS RS20200983A patent/RS60703B1/sr unknown
- 2016-09-16 US US15/267,213 patent/US10138296B2/en active Active
- 2016-09-16 HU HUE16774750A patent/HUE051496T2/hu unknown
- 2016-09-16 CN CN201680053598.8A patent/CN108137693B/zh active Active
- 2016-09-16 CA CA2997015A patent/CA2997015A1/en active Pending
- 2016-09-16 IL IL257761A patent/IL257761B2/en unknown
- 2016-09-16 AU AU2016323460A patent/AU2016323460B2/en active Active
- 2016-09-16 SI SI201630885T patent/SI3350223T1/sl unknown
- 2016-09-16 EA EA201890756A patent/EA201890756A1/ru unknown
- 2016-09-16 MA MA052643A patent/MA52643A/fr unknown
- 2016-09-16 MX MX2018003185A patent/MX2018003185A/es unknown
-
2018
- 2018-02-28 ZA ZA2018/01427A patent/ZA201801427B/en unknown
- 2018-03-16 CL CL2018000711A patent/CL2018000711A1/es unknown
- 2018-04-09 CO CONC2018/0003736A patent/CO2018003736A2/es unknown
- 2018-10-18 US US16/164,509 patent/US11220549B2/en active Active
-
2020
- 2020-08-17 CY CY20201100767T patent/CY1123499T1/el unknown
-
2021
- 2021-11-30 US US17/538,530 patent/US12162946B2/en active Active
-
2022
- 2022-01-17 JP JP2022005039A patent/JP7341259B2/ja active Active
-
2023
- 2023-06-01 AU AU2023203440A patent/AU2023203440B2/en active Active
-
2024
- 2024-11-06 US US18/939,176 patent/US20250179202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201323T1 (hr) | Protutijela koja se specifično vežu na tl1a | |
| CA2795200C (en) | Soluble human st-2 antibodies and assays | |
| CN110498854B (zh) | 一种抗金黄色葡萄球菌肠毒素b的抗体及其应用 | |
| JP2014518883A5 (enExample) | ||
| JP2012529280A5 (enExample) | ||
| KR102786245B1 (ko) | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 | |
| JP2014523401A5 (enExample) | ||
| JP2017512209A (ja) | デングウイルスに対する抗体分子およびその使用 | |
| US20240247047A1 (en) | BTLA Fusion Protein Agonists and Uses Thereof | |
| WO2015032906A4 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| KR20180094877A (ko) | 아밀로이드 베타 내 c-말단 에피토프 및 이에 대해 구조적으로 선택적인 항체 | |
| JP2013542914A5 (enExample) | ||
| JP2016512214A5 (enExample) | ||
| JP2016509585A5 (enExample) | ||
| JP2017510627A5 (enExample) | ||
| JP2013505938A5 (enExample) | ||
| JP2017530372A5 (enExample) | ||
| WO2017079835A1 (en) | Amyloid beta epitopes and antibodies thereto | |
| CN108350050A (zh) | 淀粉样蛋白β中的表位及其构象选择性抗体 | |
| JP2015500797A5 (enExample) | ||
| JP2014527396A5 (enExample) | ||
| JP2016534022A5 (enExample) | ||
| Blanchard et al. | Respiratory infections associated with anti-TNFα agents | |
| WO2016040571A1 (en) | Methods of treating autoimmune disease using a domain antibody directed against cd40l |